Thursday, May 26, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study finds mRNA vaccines induce poor neutralizing antibody response against SARS-CoV-2 variants in dialysis patients

by Medical Finance
in Coronavirus
Study: Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. Image Credit: Adao/Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

Individuals with chronic kidney disease (CKD) are highly vulnerable to infections, which could even lead to death. Such patients are highly susceptible to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease-2019 (COVID-19) pandemic. Therefore, it is crucial to understand how effective vaccine-elicited antibodies are in providing neutralizing activity and their coverage of SARS-CoV-2 variants. This could be important to inform prophylactic and therapeutic COVID-19 interventions.

To address this gap in research, scientists studied plasma samples from 130 hemodialysis (HD) and 13 peritoneal dialysis patients and showed a poor neutralizing and rapidly decaying antibody response to mRNA vaccines in such individuals. This study is published in PLoS ONE.

Study: Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. Image Credit: Adao/ShutterstockStudy: Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. Image Credit: Adao/Shutterstock


Background

COVID-19 vaccines have been instrumental in protecting against SARS-CoV-2 infection and, especially, severe COVID-19 disease. Across healthy and at-risk individuals, the mRNA-based vaccines developed by Pfizer/BioNTech (BNT-162b2) and Moderna (mRNA-1273) have shown high efficacy and safety. The exceptions were individuals with hematological malignancies, autoimmune diseases, and solid organ transplantations, as they did not mount a robust antibody response when vaccinated with these vaccines.

Research on HD patients revealed a delayed and lower serological response to vaccines. Scientists also observed a rapid decline of anti-SARS-CoV-2 antibodies. Taken together, these results imply a diminished vaccine response in end-stage kidney disease (ESKD) patients. Matters have been further complicated by the emergence of the SARS-CoV-2 Delta variant (B.1.617.2 lineage) since April 2021.

Key findings

The current study observed that dialysis patients fail to develop sufficient levels of neutralizing antibodies against emerging SARS-CoV-2 variants, even after being administered two doses of mRNA vaccines. Plasma SARS-CoV-2-specific IgG analysis revealed an overall response, to mRNA vaccines, in approximately 94% of dialysis patients. This finding is in line with other studies that report the range between 70% and 96%. In HD patients, reduced antibody responses were observed after both vaccination doses. Such analysis could help clinicians identify vaccine non-responders and form appropriate treatment strategies.

Researchers observed that 49% of the HD patients had low or negligible amounts of neutralizing antibodies and a significant reduction in neutralizing titers against SARS-CoV-2 variants. They computed that the fraction of non-responding patients was significantly higher at 77%, in the case of the SARS-CoV-2 Delta variant. This suggested that a large proportion of patients immunized with two doses of an mRNA vaccine might not develop a protective antibody response.

Follow-up data (up to 7 months after vaccination) showed a rapid decay of neutralizing antibodies. This was true both for the wild-type as well as the Delta variant. This further increased the percentage of non-responders to 84% and 90%, respectively. Scientists stated that they did not observe new cases of infection during the follow-up but could be largely driven by the low number of cases in Switzerland in the spring-summer season and the preventive measures taken by individuals.

A significant discrepancy was observed in the fraction of individuals identified as non-responders based on antibody levels and their neutralizing activity. Despite this, the correlation between these titers was high, implying that this could be utilized in defining appropriate cut-offs in the serological tests used in clinical settings to identify non-responders. Scientists stated that a SARS-CoV-2 avidity test could be used to identify non-responders, as for other infectious diseases.

It was especially observed in the case of HD patients that individuals who were never exposed to SARS-CoV-2 infection were at a much higher risk of poor antibody response after vaccination. This suggests that vaccination could boost neutralizing antibody responses in such patients after infection. The Moderna vaccine was more reactogenic and induced higher antibody titers in all individuals, compared to the Pfizer-BioNTech vaccine. This could be driven by the higher mRNA provided by one dose of the former.

Limitations

One of the major limitations of this study is a lack of a suitable control group. The results could be more robust in the presence of a control group matched on all parameters (age, gender, comorbidities, etc.), except ESKD. The number of PD patients was also quite low for meaningful inference, and the sampled patients were not balanced with respect to the type of mRNA vaccine they had received.

Conclusion

The findings documented in the current study echo the need for an additional high-dose booster mRNA vaccine among dialysis patients. This would need to be monitored with appropriate serological tests. The results also imply that certain individuals may not respond as desired to the additional boost. Such individuals should be considered for alternative treatment strategies, such as early immunotherapy with monoclonal antibodies.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Host genomes for the unique SARS-CoV-2 variant leaked into Antarctic soil metagenomic sequencing data. Image Credit: Alex.Munoz / Shutterstock

Antarctic soil sample from 2018 adds to the enigma of the COVID-19 pandemic

by Medical Finance
May 26, 2022
0

The origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has long been debated among scientists. However, prior research found...

Study: ARTIFICIAL INTELLIGENCE TOOLS FOR EFFECTIVE MONITORING OF POPULATION AT DISTANCE DURING COVID-19 PANDEMIC. RESULTS FROM AN ITALIAN PILOT FEASIBILITY STUDY (RICOVAI-19 STUDY). Image Credit: elenabsl/Shutterstock

AI based home monitoring during COVID-19 pandemic

by Medical Finance
May 26, 2022
0

In a recent study posted to the medRxiv* preprint server, an interdisciplinary team of researchers conducted an open, prospective...

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

by Medical Finance
May 26, 2022
0

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and...

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Philippines starts vaccinating children aged five to 11 against COVID-19

by Medical Finance
May 26, 2022
0

The Philippines began vaccinating children aged five to 11 against COVID-19 on Monday after initial hiccups over delayed deliveries of...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

COVID-19 preventive behaviors impacted by implicit social pressure, desire for normalcy

by Medical Finance
May 26, 2022
0

As we move into the third year of the COVID-pandemic, we still face a multitude of information and it can...

Study: Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Image Credit: Good Studio / Shutterstock.com

Danish study of long COVID in teens

by Medical Finance
May 26, 2022
0

As an aftermath of the extended lockdowns and social distancing restrictions, Coronavirus disease 2019 (COVID-19) has impacted the quality of...

Next Post
Study: A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape. Image Credit: ustas7777777 / Shutterstock.com

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Study: The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Image Credit: Marcos Homem / Shutterstock.com

Canadian study estimates incidence rate of reinfection in healthcare workers

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Genetic disease
    Computational biology in rare disease research
  • Pathology 620x480
    Grouping tumors by ‘immune archetypes’ points the way to personalized immunotherapies
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply